<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00131027</url>
  </required_header>
  <id_info>
    <org_study_id>JALSG ALL202-O</org_study_id>
    <nct_id>NCT00131027</nct_id>
  </id_info>
  <brief_title>High-Dose Methotrexate (MTX) for Adult Acute Lymphoblastic Leukemia (ALL)</brief_title>
  <official_title>Randomized Controlled Trial to Test Efficacy of High-Dose Methotrexate Consolidation Therapy for BCR-ABL-Negative Acute Lymphoblastic Leukemia in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Japan Adult Leukemia Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Japan Adult Leukemia Study Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the clinical efficacy of high-dose methotrexate
      consolidation therapy for adult patients with BCR-ABL-negative ALL.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although the multi-agent chemotherapies in current use produce complete remission for a
      majority of patients with acute lymphoblastic leukemia (ALL), the prognosis for adult ALL
      remains discouraging due to a high incidence of relapse. Optimal post-remission therapy,
      therefore, has been a matter of vital concern. In some pediatric ALL studies, the use of
      high-dose methotrexate (MTX) as a consolidation therapy, has been shown to improve outcome,
      however, there has been no randomized controlled trials to test its clinical efficacy in
      adult ALL. With this concern, the Japan Adult Leukemia Study Group (JALSG) has planned a
      prospective randomized controlled trial comparing high-dose MTX and intermediate-dose MTX for
      ALL patients who are negative for BCR-ABL. Those who are positive for BCR-ABL can participate
      in a separate protocol.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2002</start_date>
  <completion_date type="Anticipated">September 2011</completion_date>
  <primary_completion_date type="Anticipated">March 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of complete remission</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Lymphoblastic Leukemia, Acute</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HD-MTX</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ID-MTX</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daunorubicin</intervention_name>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-asparaginase</intervention_name>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>3 g/sqm (high dose)</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mercaptopurine</intervention_name>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>0.5 g/sqm (intermediate dose)</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Previously untreated BCR-ABL-negative ALL

          -  Age between 25 and 64 years

          -  Performance status between 0 and 3 (ECOG criteria)

          -  Adequate functioning of the liver (serum bilirubin level &lt; 2.0 mg/dL); kidneys (serum
             creatinine level &lt; 2.0 mg/dL); and heart (left ventricular ejection fraction greater
             than 50% and no severe abnormalities detected on electrocardiograms and
             echocardiographs).

          -  Written informed consent to participate in the trial

        Exclusion Criteria:

          -  Uncontrolled active infection

          -  Another severe and/or life-threatening disease

          -  Positive for HIV antibody and/or hepatitis B surface (HBs) antigen tests

          -  Another primary malignancy which is clinically active and/or requires medical
             interventions

          -  Pregnant and/or lactating women

          -  Past history of renal failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fumihiko Hayakawa, MD</last_name>
    <role>Study Director</role>
    <affiliation>Nagoya University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tomoki Naoe, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Nagoya University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fumihiko Hayakawa, MD</last_name>
    <email>bun-hy@med.nagoya-u.ac.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Hematology, Nagoya University Graduate School of Medicine</name>
      <address>
        <city>Nagoya</city>
        <zip>466-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fumihiko Hayakawa, MD</last_name>
      <email>bun-hy@med.nagoya-u.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Fumihiko Hayakawa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.jalsg.jp/</url>
    <description>The JALSG homepage</description>
  </link>
  <verification_date>November 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 15, 2005</study_first_submitted>
  <study_first_submitted_qc>August 15, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2005</study_first_posted>
  <last_update_submitted>November 13, 2008</last_update_submitted>
  <last_update_submitted_qc>November 13, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 14, 2008</last_update_posted>
  <keyword>acute lymphoblastic leukemia</keyword>
  <keyword>newly diagnosed</keyword>
  <keyword>BCR-ABL-negative</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
    <mesh_term>6-Mercaptopurine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

